Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery

September 3, 2026 updated by: Mayo Clinic

A Pilot Study to Evaluate the Feasibility and Safety of Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery

This study is a non-randomized, open label, phase 1 clinical trial to evaluate the fesibility and safety of intrathalamic delivery of MSCs during standard of care DBS surgery for epilepsy.

Subjects will be screened at our outpatient clinic and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained, patients will undergo a standard preoperative evaluation which includes baseline laboratory values and a high-definition MRI. Patients will then undergo a stereotactic procedure for bilateral thalamic implantation of DBS leads through the ClearPoint® system. After the thalamic target for DBS is identified, cells will be infused directly into the anterior nucleus of the thalamus previous to lead implantation.

Patients will be followed in the outpatient setting for up to a year after therapy application.

Surgical, clinical, and radiographic data will be obtained during these visits

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

To investigate the feasibility and safety of local delivery of AMSCs for epilepsy by measuring the incidence of AEs related to the study agent.

To investigate the effects of local delivery of AMSCs for epilepsy as measured by radiographic data on MRI.

Study Type

Interventional

Enrollment (Actual)

1

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Florida
      • Jacksonville, Florida, United States, 32224
        • Mayo Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants ≥ 18 years of age.
  • Participants with Drug Resistance Epilepsy as defined by the ILAE5.
  • Participants undergoing bilateral implantation of DBS leads into the anterior nucleus of the thalamus.
  • Adequate organ function as assessed by the following laboratory values within 3 weeks prior to admission to the study:
  • Serum creatinine and urea < 2 times the upper limit of normal;
  • ALT, AST and alkaline phosphatase < 3 times the upper limit of normal, and bilirubin < 2.5 mg/dL;
  • Prothrombin time ≤ 1.5 times upper limit of normal;
  • INR and PTT ≤ 1.5 times the upper limit of normal;
  • Hemoglobin ≥ 9 g/dL;
  • Platelets ≥ 100 x 10^9/L;
  • Absolute Neutrophil Count (ANC) ≥ 1.5 x 10^9/L.
  • Patient or legal guardian is able to fully understand and provide written and verbal consent for the protocol.
  • Patient is a candidate for ANT DBS based on the following criteria established by the American Society for Stereotactic and Functional Neurosurgeons:
  • Confirmed diagnosis of epilepsy by an epileptologist with focal-onset seizures, with or without generalization;
  • Failure to adequately control seizures after two (or more) appropriate and adequately-dosed anti-seizure medications;
  • Either partial-onset seizures with a localized onset in a region not amenable to resection or following failed resective surgery or focal-onset seizures with distributed or unclear onset zone.

Exclusion Criteria:

  • Patients who have undergone a prior intracranial procedure for epilepsy.
  • Patients with an intracranial tumor.
  • Confirmed pregnancy.
  • History of cancer not in remission for at least 5 years.
  • History of diabetes, chronic renal failure, or other significant underlying medical or ----immunosuppressive conditions.
  • History of drug or alcohol abuse.
  • Subjects allergic to any component of the investigational product.
  • Subjects > 75 years of age.
  • Cognitively impaired adults.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: AMSCs
A single dose of 5x10^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery
A single dose of 5x10^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of AEs related to the study agent
Time Frame: 12 months
To investigate the feasibility and safety of local delivery of AMSCs for epilepsy by measuring the incidence of AEs related to the study agent.
12 months
Radiographic effects related to the study agent
Time Frame: 12 months
To investigate the effects of local delivery of AMSCs for epilepsy as measured by radiographic data on MRI.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Sanjeet Grewal, MD, Mayo Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 23, 2024

Primary Completion (Actual)

September 3, 2026

Study Completion (Actual)

September 3, 2026

Study Registration Dates

First Submitted

February 20, 2024

First Submitted That Met QC Criteria

February 20, 2024

First Posted (Actual)

February 28, 2024

Study Record Updates

Last Update Posted (Actual)

September 8, 2026

Last Update Submitted That Met QC Criteria

September 3, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 23-009133

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.